AU2003245313A1 - Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions - Google Patents
Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositionsInfo
- Publication number
- AU2003245313A1 AU2003245313A1 AU2003245313A AU2003245313A AU2003245313A1 AU 2003245313 A1 AU2003245313 A1 AU 2003245313A1 AU 2003245313 A AU2003245313 A AU 2003245313A AU 2003245313 A AU2003245313 A AU 2003245313A AU 2003245313 A1 AU2003245313 A1 AU 2003245313A1
- Authority
- AU
- Australia
- Prior art keywords
- statins
- manufacturing
- well
- pharmaceutical compositions
- coa reductase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Surgery (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38740402P | 2002-06-10 | 2002-06-10 | |
US60/387,404 | 2002-06-10 | ||
PCT/US2003/016206 WO2003103640A1 (en) | 2002-06-10 | 2003-06-10 | Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (“statins”), novel combinations thereof as well as manufacturing of these pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2003245313A1 true AU2003245313A1 (en) | 2003-12-22 |
Family
ID=29736310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003245313A Abandoned AU2003245313A1 (en) | 2002-06-10 | 2003-06-10 | Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1531799A1 (en) |
JP (1) | JP4831965B2 (en) |
AU (1) | AU2003245313A1 (en) |
CA (1) | CA2488499C (en) |
WO (1) | WO2003103640A1 (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1599468B1 (en) | 2003-01-14 | 2007-10-03 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
DE10339354A1 (en) * | 2003-08-27 | 2005-04-07 | Beisel, Günther | Synergistic composition for treating metabolic syndrome, comprises swellable or gel-forming satiating and weight reducing agent and hypocholesterolemic and/or antidiabetic agent |
US9173847B2 (en) | 2003-10-10 | 2015-11-03 | Veloxis Pharmaceuticals A/S | Tablet comprising a fibrate |
JP5069001B2 (en) | 2003-10-10 | 2012-11-07 | ベロクシス ファーマシューティカルズ エー/エス | Solid dosage form containing fibrates |
PL1732605T3 (en) | 2004-03-29 | 2019-09-30 | Wyeth Llc | Multi-vitamin and mineral nutritional supplements |
ES2255426B1 (en) * | 2004-10-19 | 2007-08-16 | Gp Pharm, S.A. | PHARMACEUTICAL FORMULATION THAT INCLUDES MICROCAPSULES OF STATINS SUSPENDED IN ESTER ALKYLS OF POLYINSATURATED FATTY ACIDS (PUFA). |
EP1835890A2 (en) * | 2005-01-06 | 2007-09-26 | Elan Pharma International Limited | Nanoparticulate candesartan formulations |
BRPI0607537A2 (en) | 2005-04-12 | 2009-09-15 | Elan Pharma Int Ltd | nanoparticulate quinazoline derivative formulations |
ES2362534T3 (en) * | 2005-06-08 | 2011-07-07 | Kowa Company, Ltd. | NEW TRIGLICERID REDUCING AGENT. |
JP5112669B2 (en) * | 2005-09-30 | 2013-01-09 | 富山化学工業株式会社 | Aqueous suspension containing nanoparticle of poorly soluble drug |
CN101309679B (en) * | 2005-11-11 | 2013-07-24 | 持田制药株式会社 | Jelly composition |
GB0523810D0 (en) * | 2005-11-23 | 2006-01-04 | Astrazeneca Ab | Pharmaceutical compositions |
US20090181098A1 (en) * | 2006-03-07 | 2009-07-16 | Osteoscreen Ip, Llc | Hmg-Co-a Reductase Inhibitor Enhancement of Bone and Cartilage |
ES2385752T3 (en) | 2006-04-26 | 2012-07-31 | Rosemont Pharmaceuticals Ltd | Oral Liquid Compositions |
GB0613925D0 (en) | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
US10568860B2 (en) | 2006-08-30 | 2020-02-25 | Kowa Co., Ltd. | Pharmaceutical composition containing statin-encapsulated nanoparticle |
JP4896220B2 (en) * | 2007-04-27 | 2012-03-14 | 国立大学法人九州大学 | Lung disease treatment |
AU2008303129B2 (en) | 2007-09-25 | 2013-08-01 | Formulex Pharma Innovations Ltd. | Compositions comprising lipophilic active compounds and method for their preparation |
FR2937537A1 (en) * | 2008-10-29 | 2010-04-30 | Centre Nat Rech Scient | NANOPARTICLES OF STATIN |
TR200904500A2 (en) | 2009-06-10 | 2009-10-21 | Öner Levent | Methods and pharmaceutical formulations for the preparation of ezetimibe nanocrystals. |
AU2011305525B2 (en) | 2010-09-22 | 2016-08-18 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
ITFI20120268A1 (en) * | 2012-12-03 | 2014-06-04 | Diopeite Consulting Ltd | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OBESITY |
WO2015185240A1 (en) | 2014-06-04 | 2015-12-10 | Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. | Compositions containing simvastatin in omega-3 polyunsaturated fatty acids |
CN116850181A (en) | 2015-01-06 | 2023-10-10 | 艾尼纳制药公司 | Treatment and S1P 1 Methods of receptor-related disorders |
ES2929526T3 (en) | 2015-06-22 | 2022-11-29 | Arena Pharm Inc | (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl) acid L-arginine crystal salt acetic acid for use in disorders associated with the S1P1 receptor |
MA47504A (en) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | COMPOUNDS AND TREATMENT METHODS FOR PRIMITIVE BILIARY ANGIOCHOLITIS |
WO2019143981A1 (en) * | 2018-01-19 | 2019-07-25 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for delivering pharmaceutical agents |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2053000C (en) * | 1990-10-15 | 1995-08-29 | Michael J. Conder | Biosynthetic production of 6(r)-[2-(8(s)-hydroxy-2(s), 6(r)-dimethyl-1,2,6,7,8,8a(r)-hexahydronaphthyl)-ethyl]-4 (r)-hydroxy-3,4,5,6-tetrahydro-2h-pyran-2-one triol acid by enzymatic hydrolysis of lovastatin acid using an enzyme derived from__lonostachys compactiuscula |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
DK0644755T3 (en) * | 1992-06-10 | 1997-09-22 | Nanosystems Llc | Surface Modified NSAID Nanoparticles |
US5585108A (en) * | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
WO1998035666A1 (en) * | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
CA2335472C (en) * | 1998-06-19 | 2008-10-28 | Rtp Pharma Inc. | Processes to generate submicron particles of water-insoluble compounds |
JP2002536405A (en) * | 1999-02-11 | 2002-10-29 | イーデンランド、インコーポレイテッド | How to treat viral infections |
US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
AU6294501A (en) * | 2000-09-20 | 2002-04-02 | Rtp Pharma Inc | Spray drying process and compositions of fenofibrate |
ES2372746T3 (en) * | 2000-09-20 | 2012-01-26 | Jagotec Ag | STABILIZED FIBRATE MICROPARTURES. |
CN1273112C (en) * | 2001-02-22 | 2006-09-06 | 斯凯伊药品加拿大公司 | Fibrate-statin combinations with reduced fed-fasted effects |
GB0119480D0 (en) * | 2001-08-09 | 2001-10-03 | Jagotec Ag | Novel compositions |
AU2003234452A1 (en) * | 2002-05-06 | 2003-11-11 | Elan Pharma International Ltd. | Nanoparticulate nystatin formulations |
AU2003241478A1 (en) * | 2002-06-10 | 2003-12-22 | Elan Pharma International, Ltd. | Nanoparticulate sterol formulations and sterol combinations |
-
2003
- 2003-06-10 EP EP03738952A patent/EP1531799A1/en not_active Withdrawn
- 2003-06-10 AU AU2003245313A patent/AU2003245313A1/en not_active Abandoned
- 2003-06-10 JP JP2004510760A patent/JP4831965B2/en not_active Expired - Fee Related
- 2003-06-10 CA CA2488499A patent/CA2488499C/en not_active Expired - Fee Related
- 2003-06-10 WO PCT/US2003/016206 patent/WO2003103640A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CA2488499C (en) | 2013-03-19 |
WO2003103640A1 (en) | 2003-12-18 |
JP2005532352A (en) | 2005-10-27 |
EP1531799A1 (en) | 2005-05-25 |
JP4831965B2 (en) | 2011-12-07 |
CA2488499A1 (en) | 2003-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003245313A1 (en) | Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions | |
AU2000264559A1 (en) | Pharmaceutical compositions comprising a hmg coa reductase inhibitor | |
AU2002246411A1 (en) | Inclusion compounds of fumagillol derivative or its salt, and pharmaceutical compositions comprising the same | |
IL162118A0 (en) | Pharmaceutical compositions containing an orally active taxane derivative | |
AU2002363236A1 (en) | Compounds, pharmaceutical compositions and methods of use therefor | |
AU2003291103A1 (en) | Pharmaceutical composition | |
AU2003249611A1 (en) | Synthesis of metal compounds useful as cathode active materials | |
AU2003218758A1 (en) | Derivatives of 1-phenyl-3-phenylpyrazole as herbicides | |
AU2003278393A1 (en) | New use for pharmaceutical composition | |
WO2005014539A3 (en) | Pyrrole-based hmg-coa reductase inhibitors | |
AU2002310798A1 (en) | Pharmaceutical compositions comprising a hmg-coa reductase inhibitor | |
WO2005005389A3 (en) | Malonamide derivatives | |
AU2003245504A1 (en) | Pharmaceutical compositions for drugs having ph-dependentsolubility | |
WO2005105079A3 (en) | Novel imidazoles | |
AU2003250172A1 (en) | Compositions comprising hmg-coa reductase inhibitor | |
AU2002364468A1 (en) | Solid orally-dispersible pharmaceutical formulation | |
AU2002356646A1 (en) | Pharmaceutical compositions for the pulmonary delivery of aztreonam | |
WO2007025774A3 (en) | Cysteine protease inhibitors | |
AU2002314566A1 (en) | Novel curcumin derivatives | |
EP1260217A3 (en) | Simethicone as weight gain enhancer for coating compositions | |
BRPI0417138A (en) | n-alkyl pyrroles as hmg coa reductase inhibitors | |
AU2002249486A1 (en) | Macromolecular compounds as potential anti-inflammatory agents | |
AU2003274410A1 (en) | Pharmaceutical compositions of ganciclovir | |
AU2003238896A1 (en) | Stabilized pharmaceutical compositions containing benzimidazole compounds | |
AU2003282231A1 (en) | Antiproliferative 2-(heteroaryl)-aminothiazole compounds, pharmaceutical compositions and methods for their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |